Test Performance and Clinical Utility of the Cobas Eplex Blood Culture Identification Fungal Pathogen Panel

Area of Science:

• Clinical Microbiology
• Infectious Diseases
• Diagnostic Technology

Background:

• Accurate identification of fungal pathogens is crucial for effective antifungal therapy.
• Existing methods for fungal identification can be time-consuming, delaying appropriate treatment.
• The Roche cobas eplex blood culture identification fungal pathogen panel (BCID-FP) was developed for rapid fungal pathogen detection.

Purpose of the Study:

• To evaluate the performance and clinical utility of the Roche cobas eplex BCID-FP assay.
• To compare the accuracy and speed of BCID-FP against traditional culture methods and another diagnostic panel.
• To assess the impact of BCID-FP implementation on antifungal treatment strategies and patient outcomes.

Main Methods:

• Retrospective analysis of BCID-FP performance against blood culture results over a 3-year period.
• Comparison of BCID-FP accuracy with the T2Dx Candida panel.
• Clinical utility assessment by comparing patient records pre- and post-BCID-FP implementation, focusing on antifungal prescribing patterns and clinical outcomes.

Main Results:

• BCID-FP demonstrated high positive percent agreement (91.7%) with culture for fungal pathogen identification.
• Excellent PPA was observed for key Candida species and Candida neoformans; lower for Candida lusitaniae and Fusarium spp.
• Implementation of BCID-FP led to a significant increase in recommendations for antifungal de-escalation and reduced time to identification compared to culture.

Conclusions:

• The Roche cobas eplex BCID-FP assay is a valuable tool for rapid and accurate identification of fungal pathogens in blood cultures.
• While the assay offers diagnostic advantages, timely integration of results into clinical decision-making is essential for optimizing patient care.
• Further studies may be warranted to address performance for less common fungal pathogens.